

Research Paper

Translational Potential of Baicalein in Mitigating RSL3-Induced Ferroptosis in Fibroblasts: Implications for Therapeutic Interventions

Pao-Jen Kuo^{1†}, Cheng-Shyuan Rau^{2†}, Yi-Chan Wu¹, Chia-Wen Tsai¹, Chia-Jung Wu¹, Chia-Wei Lin¹ and Ching-Hua Hsieh^{1✉}

1. Department of Plastic Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan.
2. Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 83301, Taiwan.

† These authors contributed equally to this work as the first authors.

✉ Corresponding author: Ching-Hua Hsieh, Email: m93chinghua@gmail.com; Tel.: 886-7-3454746.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2023.11.06; Accepted: 2024.04.19; Published: 2024.05.13

Abstract

Background: Ferroptosis is an iron-driven cell-death mechanism that plays a central role in various diseases. Recent studies have suggested that baicalein inhibits ferroptosis, making it a promising therapeutic candidate.

Materials and Methods: Fibroblast cultures were treated with different agents to determine the effects of baicalein on ferroptosis. Ferroptosis-related gene expression, lipid peroxidation, and post-treatment cellular structural changes were measured using real-time quantitative polymerase chain reaction, C11-BODIPY dye, and transmission electron microscopy, respectively.

Results: Baicalein significantly inhibited rat sarcoma virus selective lethal 3-induced ferroptosis in fibroblasts. Moreover, in baicalein-treated groups, reduced ferroptosis-related gene expression, decreased lipid peroxidation, and maintained cell structure was observed when compared with those of the controls.

Discussion: The ability of baicalein to counteract RSL3-induced ferroptosis underscores its potential protective effects, especially in diseases characterized by oxidative stress and iron overload in fibroblasts.

Conclusion: Baicalein may serve as a potent therapeutic agent against conditions in which ferroptosis is harmful. The compound's efficacy in halting RSL3-triggered ferroptosis in fibroblasts paves the way for further *in vivo* experiments and clinical trials.

Keywords: Baicalein; Rat sarcoma virus selective lethal 3 (RSL3); Ferroptosis; Fibroblasts; Nuclear factor erythroid 2-related factor

Introduction

Ferroptosis is a recently discovered type of controlled cell death that is characterized by lipid peroxide and iron-dependent reactive oxygen species buildup, which can lead to oxidative damage to cellular membranes [1-3]. Moreover, ferroptosis is characterized by distinct morphological changes, including decreased mitochondrial volume, increased mitochondrial membrane density, and the absence of typical apoptotic features [4]. Dysregulation of ferroptosis has been linked to several illnesses including neurological conditions [5-7], cardiovascular diseases [8, 9], acute and chronic kidney injury [10-12], ischemia-reperfusion injury [13, 14],

and cancer therapy [15-17], making it an active research topic in cell biology and medicine.

The gene expression of these factors can be influenced by various signaling pathways and transcriptional regulators involved in ferroptosis. These include nuclear factor erythroid 2-related factor 2 (Nrf2) [18-21], the ferroptosis suppressor protein glutathione peroxidase 4 (GPX4) [22-24], the tumor suppressor protein p53 [25-27], and System xc-, a cystine-glutamate antiporter consisting of solute carrier (SLC)3A2 and SLC7A11, which is crucial for importing cystine into the cell in exchange for glutamate [28, 29]. The small-molecule compound rat

sarcoma virus-selective lethal 3 (RSL3) is frequently employed as a ferroptosis activator, inhibits the function of GPX4, and causes a buildup of lipid peroxides, which initiates a chain reaction of lipid peroxidation. [30, 31]. Lipid peroxidation disrupts the fluidity and integrity of the lipid bilayer, leading to membrane destabilization, permeabilization, cellular dysfunction, and programmed cells [30, 31].

Fibroblasts are a type of connective tissue cell and play essential roles in maintaining tissue structure, wound healing, and tissue repair. The induction of ferroptosis in fibroblasts has significant implications for various biological processes and pathological conditions, including tissue homeostasis, tissue fibrosis, wound healing, oxidative stress, and therapeutic interventions in the tumor microenvironment [32-38], thus making it a topic of intense interest in cell biology and biomedical research.

Baicalein is a flavonoid with a rich history in traditional medicine owing to its antioxidative and anti-inflammatory properties. Hence, it was considered as a modern therapeutic agent in this study. An inquiry aimed at screening a library of natural chemicals as potential ferroptosis inhibitors revealed that baicalein has potent inhibitory effects against erastin-induced ferroptosis in pancreatic cancer cells [39]. Traditional Chinese and Japanese herbal medicines have long used baicalein, a natural flavonoid found in the roots of *Scutellaria baicalensis* and *Scutellaria lateriflora*, to treat bacterial and viral illnesses [40]. Furthermore, baicalein exhibits antioxidative effects by scavenging reactive oxygen species, inhibiting lipid peroxidation, and attenuating oxidative damage associated with ferroptosis [41-45].

Although baicalein has shown promising potential for reducing ferroptosis in experimental studies, its effect on fibroblast ferroptosis is not well understood. This study aimed to determine the effects of baicalein on RSL3-induced ferroptosis in primary human fibroblasts. This study serves as a crucial link between basic cellular studies and clinical applications and lays the groundwork for subsequent *in vivo* studies and clinical trials. This approach is pivotal in moving beyond the theoretical approach and showcases a translational treatment with potential as a real-world medical solution.

Materials and Methods

Chemicals and reagents

Human skin fibroblasts were sourced from the Bioresource Collection and Research Center, Taiwan, under catalog number CG1639. Dulbecco's modified Eagle medium (DMEM) and Hanks' balanced salt solution (HBSS) were obtained from GIBCO (Grand

Island, NY, USA). Ferroptosis inducers RSL3, baicalein and ferrostatin-1, were obtained from Sigma-Aldrich (St. Louis, MO, USA). The Kelch-like epichlorohydrin-associated protein 1 (Keap1)-Nrf2-antioxidant responsive element (ARE) antibody panel, cataloged under ARG30345, was sourced from Arigo Biolaboratories Corp (Hsinchu City, Taiwan). CytoScan water-soluble tetrazolium salt (WST-1) Cell Proliferation Assay kit (catalog number ab65475) was purchased from Abcam (Cambridge, UK). Horseradish peroxidase (catalogue number: AP132P) was purchased from Millipore (Burlington, MA, USA). The RNeasy Mini Kit (catalog number: 217004) was purchased from Qiagen (Hilden, Germany). Both the High-Capacity complementary (cDNA) Reverse Transcription Kit (catalog 4368814) and Power SYBR Green PCR Master Mix (catalog 4367659) were procured from Applied Biosystems (Foster City, CA, USA). Finally, C11-BODIPY 581/591 (catalog number D3861) was purchased from Thermo Fisher Scientific (Waltham, MA, USA).

Cell viability

Cell viability was measured using the CytoScan WST-1 Cell Proliferation Assay, in which metabolically active cells reduce WST-1, resulting in the production of a colored formazan product. The number of viable cells was determined based on color intensity, which directly corresponded to cell viability. Briefly, fibroblasts were seeded into transparent 96-well microplates, with each well containing 10,000 cells. The cells were allowed to grow for a 24-h period in a moist environment with 5% CO₂. These fibroblasts were then reconstituted in DMEM devoid of serum but enriched with 10% fetal bovine serum and 1% penicillin/streptomycin. Subsequent treatments involved introducing RSL3 in concentrations ranging from 0–2.0 μM and baicalein in dosages spanning from 0–1000 μM. The cells were allowed to grow and multiply, and after 0–16 h following RSL3 treatment, the cell culture medium was replaced with the WST-1 reagent. A microplate reader (Thermo Fisher Scientific) with a spectrophotometric function set at a wavelength of 450–490 nm, was used to measure formazan absorbance. Experiments were performed with six samples per group.

Determination of Keap1/Nrf2/NQO1 & HO-1 activation

Western blotting was used to determine the activation of the Keap1/Nrf2/nicotinamide adenine dinucleotide phosphate hydrogen quinone dehydrogenase 1 (NQO1) and heme oxygenase 1 (HO-1) pathways. Fibroblast cytosolic proteins, which were

either treated with phosphate-buffered saline (PBS) as a control or exposed to 0.5 μ M RSL3 with or without 100 μ M baicalein for 24 h, were isolated. The proteins were electrophoretically separated on polyacrylamide gels and transferred onto polyvinylidene fluoride membranes. These membranes underwent an overnight incubation at 4 °C with primary antibodies targeting Keap1, Nrf2, NQO1, and HO-1, sourced from the Keap1-Nrf2-ARE antibody panel kit. Primary antibodies were used at dilutions ranging from 1:500 to 1:1000. Following this, membranes were thoroughly washed in a 0.1% Tris-buffered saline/Tween 20 solution, maintained at 37 °C. Thereafter, the membranes were incubated for 2 h with a secondary antibody conjugated to horseradish peroxidase. The fluorescent signals were visualized and quantified using a FluorChem SP imaging device (Alpha Innotech, San Leandro, CA, USA). Experiments were performed with six samples per group.

Determination of ferroptosis-related gene expression

Real-time quantitative polymerase chain reaction (PCR) was used to measure the expression of ferroptosis-related genes. Fibroblasts (1×10^5) were cultured in a 10-cm dish and exposed to PBS (control group) and to 0.5 μ M RSL3 in the presence or absence of baicalein (50 or 100 μ M) or 10 μ M ferrostatin-1 for 24 h. The collected cells were subjected to total RNA extraction using RNeasy Mini Kits, and the concentration of RNA was determined using an SSP-3000 NanoDrop spectrophotometer (Infinigen Biotech, City of Industry, CA, USA). The extracted RNA was subsequently transcribed into cDNA using a high-capacity cDNA Reverse Transcription kit. To amplify the cDNA, The Power SYBR Green PCR Master Mix was used to amplify the cDNA along with specific designed primers, including cyclooxygenase-2 (COX-2; forward: 5'-ACGATCCCTCCCTTACCATCAAA-3'; reverse: 5'-TCGGGAGTACTACTCGATTGTCAACG-3'); acyl-CoA synthetase long-chain family member 4 (ACSL4; forward: 5'-GTGGTTCTACTGGCCGACCTAAG-3'; reverse: 5'-CTGCAGCCATAGGTAAAGCAAGATATCTC-3'); prostaglandin-endoperoxide synthase 2 (PTGS2; forward: 5'-AGGGTTGCTGGTGGTAGGAAT-3'; reverse: 5'-TAGAGTGCTTCCAACCTCTGCAGACA-3'); SLC3A2 (forward: 5'-GACTTGCTGTTGACTAGCTCATACCT-3'; reverse: 5'-GGAGAAGTTGAGCCGCAAGA-3'); SLC7A11 (forward: 5'-CCAGATATGCATCGTCCTTCAAGGT-3'; reverse: 5'-ATAATACGCAGGGACTCCAGTCAG-3'); GPX4 (forward: 5'-TAACGAAGAGATCAAAGAGTTCGCCG-3'; reverse: 5'-GGTGAAGTTCACCTTGATGGCATT-3'); and ferritin heavy chain 1 (FTH1; forward:

5'-CTTACTACTTIGACCGCGAIGATGTG-3'; reverse: 5'-CACTCCATTGCATTCAGCCCG-3'). The primers for mouse glyceraldehyde 3-phosphate dehydrogenase as an internal control were 5'-GGAGAGTGTTCCTCGTCCC-3' (forward) and 5'-ATGAAGGGGTCGTTGATGGC-3' (reverse). The Power SYBR Green PCR Master Mix with specific primers was used for cDNA amplification. The expression of ferroptosis-related genes was quantified using the 2-Ct method with normalized cycle threshold (Ct) values. All data were presented as the average \pm standard deviation. To analyze the differences between group averages, one-way analysis of variance was utilized, followed by a post-hoc test using Fisher's least significant difference method. Experiments were performed with six samples per group. Statistical significance was set at $P < 0.05$.

Determination of cell peroxidation

C11-BODIPY is a lipophilic fluorescent dye that is selectively incorporated into cellular membranes, making it useful for monitoring lipid peroxidation and oxidative stress. When C11-BODIPY is incorporated into membranes, its fluorescence emission spectrum shifts depending on its oxidation state. In an unoxidized state, it emits green fluorescence at a wavelength of approximately 581 nm, whereas upon oxidation, it undergoes a shift and emits red fluorescence at approximately 591 nm. This allows for monitoring of lipid peroxidation and oxidative stress in cells and tissues. After the specified treatment duration, cells were rinsed with PBS, collected using trypsin, and then suspended in 500 μ l of HBSS with 2 μ l of C11-BODIPY 581/591. This mixture was allowed to incubate for 15 min at 37 °C inside a tissue culture incubator. Post incubation, cells were cleaned using HBSS, spun down at $3,000 \times g$ for a span of 5 min, and subsequently suspended in 200 μ l of PBS. For each replicate, at least 10,000 events were gathered and evaluated using a flow cytometer (Becton Dickinson, Rutherford, NJ, USA) at a wavelength of 488 nm. Experiments were performed with six samples per group.

Transmission electron microscopy (TEM) analysis

Ultrastructural modifications of the cells were analyzed using an HT-7700 transmission electron microscope (Hitachi, Tokyo, Japan). In the procedure, fibroblasts were either treated with PBS as a control or exposed to 0.5 μ M RSL3, with or without the addition of 100 μ M baicalein for 24 h. Following treatment, the cells were washed twice with PBS, centrifuged for collection, and immersed in agar. Once the agar

solidified, cell aggregates were fixed using 2.5% glutaraldehyde in 0.1% sodium chloride buffer. After rinsing, dehydration, and embedding, samples were sectioned and examined under a transmission electron microscope at 100 kV.

Results

Baicalein treatment reduced Nrf2/HO-1 activation caused by RSL3 stimulation

RSL3 treatment of fibroblasts for 16 h caused a substantial dose-dependent reduction in cell viability, with a half-maximal inhibitory concentration (IC_{50}) of 0.33 μ M (Figure 1A). Cell viability of the fibroblasts treated with 0.5 μ M RSL3 significantly decreased at 4 h and persisted till at least at 16 h (Figure 1B). Additionally, the 500 μ M baicalein treatment had no discernible effect on fibroblast cell vitality. The IC_{50} of baicalein treatment for fibroblasts was 928 μ M (Figure 1C). Baicalein at concentrations of 50, 100, and 500 μ M improved fibroblast vitality at 24 h later following 0.5 μ M RSL3 therapy (Figure 1D). Except for the more dispersed distribution of the cells, there was no discernible morphological change in each cell under light microscopy (Figure 1E). As shown in Figure 2, the expression of Nrf2, as well as downstream NQO1 and HO-1, significantly increased after the fibroblasts

0.5 μ M RSL3 treatment for 16 h. Activation of HO-1 and Nrf2 expression was significantly lowered by the addition of 100 μ M baicalein; however, the upregulation of NQO1 by RSL3 treatment was not significantly reduced by the addition of baicalein. The expression of Keap1 was not significantly altered following RSL3 treatment in the presence or absence of baicalein.

Expression of ferroptosis-related genes and cell peroxidation

Figure 3A demonstrates that when treated with 0.5 μ M RSL3 for 16 h, there was an increase in the expression of ferroptosis-associated genes such as COX-2, ACSL4, PTGS2, SLC3A2, and SLC7A11. Concurrently, there was a reduction in GPX4 and FTH1 levels, which are typically reduced during ferroptosis. Moreover, the addition of 50 and 100 μ M baicalein, or 10 μ M ferrostatin-1 significantly reduced the over-expression of COX-2 and increased the down-regulated GPX4 and FTH1 levels. Flow cytometry detecting C11-BODIPY revealed that RSL3 treatment increased cell peroxidation, which was significantly reduced by adding 50 and 100 μ M baicalein, or 10 μ M ferrostatin-1 (Figure 3B).




Figure 1. Cell viability of fibroblasts. Cell viability was detected using CytoScan WST-1 Cell Proliferation Assay upon treatment with (A) 0.5–2.0 μ M RSL3 for 16 h; (B) 0.5 μ M RSL3 for 0–16 h; or (C) 0–1000 μ M baicalein for 16 h. IC_{50} indicates the half maximal inhibitory concentration; (D) The cell viability at 24 h later following additional of 50, 100, or 500 μ M baicalein in the fibroblastes treated by 0.5 μ M RSL3 for 16 h; (E) Morphology of fibroblasts under optic microscopy at magnifications of 200 and 400 \times in the absence or presence of 0.5 μ M RSL3 treatment for 16 h, with or without subsequent 100 μ M baicalein therapy for 24 h. WST-1: water-soluble tetrazolium salt; RSL3: rat sarcoma virus selective lethal 3.




Figure 2. Protein expression of Keap1/Nrf2/NQO1 & HO-1. Detection of Keap1/Nrf2/NQO1 & HO-1 activation using western blotting in fibroblasts treated with PBS as a control or treated with 0.5 μ M RSL3 in the presence or absence of 100 μ M baicalein for 24 h. * Indicates a significant change ($P < 0.05$) in the samples ($n = 6$). The error bar represents the standard error of mean. Keap1: Kelch-like epichlorohydrin-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; NQO1: nicotinamide adenine dinucleotide phosphate hydrogen quinone dehydrogenase 1; HO-1: heme oxygenase 1; PBS: phosphate-buffered saline; RSL3: rat sarcoma virus selective lethal 3.

TEM analysis

The mitochondrial ultrastructure of the fibroblasts treated with 0.5 μ M RSL3 in the presence or absence of 100 μ M baicalein for 24 h was detected using TEM. Cells treated with PBS were used as controls. Ferroptotic cells typically had smaller-than-normal mitochondria, dense mitochondrial membranes, few cristae, and ruptured outer mitochondrial membranes (Figure 4A). These characteristics were diminished after 100 μ M baicalein treatment.

Discussion

Keap1 detects oxidative and electrophilic disturbances in the cytoplasm. When confronted with oxidative stress or electrophiles, Keap1 undergoes changes that cause Nrf2 to detach from it. Consequently, Nrf2 becomes stable and accumulates in the cytoplasm. Subsequently, Nrf2 moves to the nucleus and attaches to DNA sequences called AREs [46-48]. This connection initiates the transcription of several protective genes such as HO-1 [46-48] and NQO1 [49-51]. HO-1 is vital for protection against oxidative stress and for ensuring cellular balance. The protein breaks down haem, which is found in hemoglobin and similar proteins, into biliverdin, iron, and carbon monoxide. Biliverdin is transformed into bilirubin,

which is known for its antioxidant benefits [46-48]. In contrast, NQO1 aids in detoxifying quinones, thereby helping to shield cells from oxidative harm and potential carcinogenic effects [49-51].

Numerous studies have demonstrated the anti-ferroptotic capabilities of baicalein [41-45]. In rat cardiomyocytes, baicalein countered ferroptosis triggered by ischemia/reperfusion by limiting the build-up of reactive oxygen species and malondialdehyde [42]. Baicalein also protected against RSL3-induced ferroptosis in melanocytes, primarily by boosting GPX4 levels [43]. In mice, targeting ferroptosis using baicalein led to improved survival rates after total-body irradiation [45]. Notably, baicalein effectively halts ferroptosis through 12/15-lipoxygenases-driven lipid peroxidation, presenting neuroprotective effects in cases such as post-trauma FeCl₃-induced epileptic seizures post-trauma [44] and traumatic brain injuries [41, 52]. Notably, baicalein's anti-ferroptosis process surpasses that of established ferroptosis inhibitors such as ferrostatin-1 and liproxstatin-1 [53]. Recent findings have also highlighted RSL3's role in inducing ferroptosis, as evidenced by the disruption of associated genes, mitochondrial dysfunction, and escalated cell peroxidation in cultured fibroblasts. Additionally, baicalein curtails RSL3-driven ferroptosis, and its

anti-ferroptosis effect is linked to activation of the Nrf2/HO-1 signaling pathway. This is achievable even with other recognized inhibitors such as ferrostatin-1. Therefore, baicalein holds promise as a treatment for cancer [36, 54] or liver fibrosis, in which fibroblasts significantly influence disease progression [55].

In the evolving landscape of biomedical research, ferroptosis has emerged as a critical area with substantial implications for various clinical conditions [56, 57], including cancer, neurodegeneration, and ischemic injury. The current research, which focuses on the inhibition of RSL3-induced ferroptosis in fibroblasts using baicalein, positions

itself at the forefront of translational medicine. This study bridges this significant gap by exploring the effects of baicalein in a novel context, being its interaction with fibroblasts under ferroptotic stress.

However, the pioneering exploration of the effects of baicalein on RSL3-induced ferroptosis in fibroblasts has limitations. Primarily, the study focuses exclusively on *in vitro* models, which, although informative, cannot fully replicate the complex *in vivo* environment. This limitation highlights the need for subsequent animal studies to validate these findings and explore their systemic effects. Additionally, the scope of the study was confined to a single cell type, warranting further




Figure 3. Expression of ferroptosis-related genes and peroxidation. (A) Real-time quantitative polymerase chain reaction of ferroptosis-related genes in 1×10^5 fibroblasts exposed to PBS (control) or to $0.5 \mu\text{M}$ RSL3 in the presence or absence of 50 or $100 \mu\text{M}$ baicalein or $10 \mu\text{M}$ ferrostatin-1 for 24 h. * Significant change ($P < 0.05$) compared with the control values ($n = 6$). # Significant change ($P < 0.05$) compared with those receiving RSL3 treatment. The error bar represents the standard error of mean. (B) Expression of C11-BODIPY detected using flow cytometry in those fibroblasts under the same conditions listed above. PBS: phosphate-buffered saline; RSL3: rat sarcoma virus selective lethal 3.




Figure 4. Representative images of the mitochondrial morphology. Mitochondrial shrinkage with decreased cristae and increased membrane density characterized the typical morphology of cells undergoing ferroptosis. Magnification $30\times\text{K}$ (top row), $50\times\text{K}$ (bottom row).

research across different cell types and tissues to understand its broader implications. Furthermore, although this research provides valuable insights, it does not address the potential side effects or toxicity of baicalein at therapeutic doses, which are crucial for clinical translation. Moreover, while this is not the initial study to demonstrate that baicalein inhibits cellular ferroptosis for therapeutic purposes, the results will contribute to the existing body of knowledge in this field. Nevertheless, additional research into the underlying mechanism is necessary to fully exploit the therapeutic capabilities of baicalein.

Conclusion

The findings of this study highlight the protective role of baicalein against RSL3-induced ferroptosis, thereby offering promising insights for drug development. Moreover, the study suggests potential avenues for the treatment of diseases in which ferroptosis plays a pivotal role.

Abbreviations

RSL3: rat sarcoma virus selective lethal 3; Nrf2: nuclear factor erythroid 2-related factor 2; GPX4: glutathione peroxidase 4; PCR: polymerase chain reaction; SLC: solute carrier; DMEM: Dulbecco's modified Eagle medium; HBSS: Hanks' balanced salt solution; Keap1: Kelch-like epichlorohydrin-associated protein 1; ARE: antioxidant responsive element; cDNA: complementary; WST-1: water-soluble tetrazolium salt; NQO1: nicotinamide adenine dinucleotide phosphate hydrogen quinone dehydrogenase 1; HO-1: heme oxygenase 1; PBS: phosphate-buffered saline; COX-2: cyclooxygenase-2; ACSL4: acyl-CoA synthetase long-chain family member 4; PTGS2: prostaglandin-endoperoxide synthase 2; FTH1: ferritin heavy chain 1; TEM: transmission electron microscopy; IC₅₀: half-maximal inhibitory concentration.

Acknowledgments

We appreciate the support provided by the Genomic and Proteomic Core Laboratory of the Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital.

Funding

This research was funded by the Chang Gung Memorial Hospital (grant numbers CMRPG8J1171 and CMRPG8L0451 to P.-J. K.).

Author contributions

Writing the original draft, P. J. K.; Funding acquisition, P. J. K.; Resources, C.-S. R.; Methodology,

Y.-C. W., C.-W. T., C.-J. W., and C.-W.L.; Conceptualization, C.-H. H.; Supervision, C.-H. All the authors have read and agreed to the published version of this manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

- Chen X, Li X, Xu X, Li L, Liang N, Zhang L, et al. Ferroptosis and cardiovascular disease: role of free radical-induced lipid peroxidation. *Free Radic Res.* 2021; 55: 405-15.
- Xu L, Liu Y, Chen X, Zhong H, Wang Y. Ferroptosis in life: To be or not to be. *Biomed Pharmacother.* 2023; 159: 114241.
- Yang WS, Stockwell BR. Ferroptosis: Death by Lipid Peroxidation. *Trends Cell Biol.* 2016; 26: 165-76.
- Wang H, Liu C, Zhao Y, Gao G. Mitochondria regulation in ferroptosis. *Eur J Cell Biol.* 2020; 99: 151058.
- Costa J, Barbosa DJ, Silva V, Benfeito S, Borges F, Remião F, et al. Research Models to Study Ferroptosis's Impact in Neurodegenerative Diseases. *Pharmaceutics.* 2023; 15.
- Long H, Zhu W, Wei L, Zhao J. Iron homeostasis imbalance and ferroptosis in brain diseases. *MedComm (2020).* 2023; 4: e298.
- Wang Y, Wu S, Li Q, Sun H, Wang H. Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes. *Adv Sci (Weinh).* 2023; e2300325.
- Fratta Pasini AM, Stranieri C, Busti F, Di Leo EG, Girelli D, Cominacini L. New Insights into the Role of Ferroptosis in Cardiovascular Diseases. *Cells.* 2023; 12.
- Xu J, Pi J, Zhang Y, Zhou J, Zhang S, Wu S. Effects of Ferroptosis on Cardiovascular Diseases. *Mediators Inflamm.* 2023; 2023: 6653202.
- Guo R, Duan J, Pan S, Cheng F, Qiao Y, Feng Q, et al. The Road from AKI to CKD: Molecular Mechanisms and Therapeutic Targets of Ferroptosis. *Cell Death Dis.* 2023; 14: 426.
- Li P, Yu J, Huang F, Zhu YY, Chen DD, Zhang ZX, et al. SLC7A11-associated ferroptosis in acute injury diseases: mechanisms and strategies. *Eur Rev Med Pharmacol Sci.* 2023; 27: 4386-98.
- Yang L, Liu Y, Zhou S, Feng Q, Lu Y, Liu D, et al. Novel insight into ferroptosis in kidney diseases. *Am J Nephrol.* 2023; 1.
- Han X, Zhang J, Liu J, Wang H, Du F, Zeng X, et al. Targeting ferroptosis: a novel insight against myocardial infarction and ischemia-reperfusion injuries. *Apoptosis.* 2023; 28: 108-23.
- Zhao K, Chen X, Bian Y, Zhou Z, Wei X, Zhang J. Broadening horizons: The role of ferroptosis in myocardial ischemia-reperfusion injury. *Naunyn Schmiedeberg Arch Pharmacol.* 2023.
- Cardona CJ, Montgomery MR. Iron regulatory proteins: players or pawns in ferroptosis and cancer? *Front Mol Biosci.* 2023; 10: 1229710.
- Chen Z, Wang W, Abdul Razak SR, Han T, Ahmad NH, Li X. Ferroptosis as a potential target for cancer therapy. *Cell Death Dis.* 2023; 14: 460.
- Lee J, Roh JL. Unleashing Ferroptosis in Human Cancers: Targeting Ferroptosis Suppressor Protein 1 for Overcoming Therapy Resistance. *Antioxidants (Basel).* 2023; 12.
- Babaei-Abraki S, Karamali F, Nasr-Esfahani MH. Ferroptosis: The functions of Nrf2 in human embryonic stem cells. *Cell Signal.* 2023; 106: 110654.
- Lane DJR, Alves F, Ayton SJ, Bush AI. Striking a NRF2: The Rusty and Rancid Vulnerabilities Toward Ferroptosis in Alzheimer's Disease. *Antioxid Redox Signal.* 2023; 39: 141-61.
- Lee J, Roh JL. Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer. *Biochim Biophys Acta Mol Basis Dis.* 2023; 1869: 166788.
- Shakya A, McKee NW, Dodson M, Chapman E, Zhang DD. Anti-Ferroptotic Effects of Nrf2: Beyond the Antioxidant Response. *Mol Cells.* 2023; 46: 165-75.
- Chen M, Shi Z, Sun Y, Ning H, Gu X, Zhang L. Prospects for Anti-Tumor Mechanism and Potential Clinical Application Based on Glutathione Peroxidase 4 Mediated Ferroptosis. *Int J Mol Sci.* 2023; 24.
- Lee J, Roh JL. Targeting GPX4 in human cancer: Implications of ferroptosis induction for tackling cancer resilience. *Cancer Lett.* 2023; 559: 216119.
- Liu Y, Wan Y, Jiang Y, Zhang L, Cheng W. GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment. *Biochim Biophys Acta Rev Cancer.* 2023; 1878: 188890.
- Xu R, Wang W, Zhang W. Ferroptosis and the bidirectional regulatory factor p53. *Cell Death Discov.* 2023; 9: 197.
- Gao N, Tang AL, Liu XY, Chen J, Zhang GQ. p53-Dependent ferroptosis pathways in sepsis. *Int Immunopharmacol.* 2023; 118: 110083.
- Wang L, Pan S. The regulatory effects of p53 on the typical and atypical ferroptosis in the pathogenesis of osteosarcoma: A systematic review. *Front Genet.* 2023; 14: 1154299.

28. Liu MR, Zhu WT, Pei DS. System Xc(-): a key regulatory target of ferroptosis in cancer. *Invest New Drugs*. 2021; 39: 1123-31.
29. Tu H, Tang LJ, Luo XJ, Ai KL, Peng J. Insights into the novel function of system Xc- in regulated cell death. *Eur Rev Med Pharmacol Sci*. 2021; 25: 1650-62.
30. Imai H, Matsuoka M, Kumagai T, Sakamoto T, Kourouma T. Lipid Peroxidation-Dependent Cell Death Regulated by GPx4 and Ferroptosis. *Curr Top Microbiol Immunol*. 2017; 403: 143-70.
31. Nguyen KA, Conilh L, Falson P, Dumontet C, Boumendjel A. The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. *Eur J Med Chem*. 2022; 244: 114863.
32. Han Z, Zheng L, Luo D, Pang N, Yao Y. Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis. *Ann Hematol*. 2023; 102: 1229-37.
33. Li S, Li Y, Wu Z, Wu Z, Fang H. Diabetic ferroptosis plays an important role in triggering on inflammation in diabetic wound. *Am J Physiol Endocrinol Metab*. 2021; 321: E509-e20.
34. Liu J, Pan Z, Tong B, Wang C, Yang J, Zou J, et al. Artesunate protects against ocular fibrosis by suppressing fibroblast activation and inducing mitochondria-dependent ferroptosis. *Faseb j*. 2023; 37: e22954.
35. Pei Z, Qin Y, Fu X, Yang F, Huo F, Liang X, et al. Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. *Redox Biol*. 2022; 57: 102509.
36. Qi R, Bai Y, Li K, Liu N, Xu Y, Dal E, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. *Drug Resist Updat*. 2023; 68: 100960.
37. Wu A, Feng B, Yu J, Yan L, Che L, Zhuo Y, et al. Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis. *Redox Biol*. 2021; 46: 102131.
38. Xing L, Dong W, Chen Y, Dai W, Xiao X, Liu Z, et al. Fibroblast ferroptosis is involved in periodontitis-induced tissue damage and bone loss. *Int Immunopharmacol*. 2023; 114: 109607.
39. Xie Y, Song X, Sun X, Huang J, Zhong M, Lotze MT, et al. Identification of baicalein as a ferroptosis inhibitor by natural product library screening. *Biochem Biophys Res Commun*. 2016; 473: 775-80.
40. Huang Y, Tsang SY, Yao X, Chen ZY. Biological properties of baicalein in cardiovascular system. *Curr Drug Targets Cardiovasc Haematol Disord*. 2005; 5: 177-84.
41. Ye Z, Zhang F, Wang P, Ran Y, Liu C, Lu J, et al. BAICALEIN RELIEVES BRAIN INJURY VIA INHIBITING FERROPTOSIS AND ENDOPLASMIC RETICULUM STRESS IN A RAT MODEL OF CARDIAC ARREST. *Shock*. 2023; 59: 434-41.
42. Wang IC, Lin JH, Lee WS, Liu CH, Lin TY, Yang KT. Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocytes. *Int J Cardiol*. 2023; 375: 74-86.
43. Yang M, Li X, Li H, Zhang X, Liu X, Song Y. Baicalein inhibits RLS3-induced ferroptosis in melanocytes. *Biochem Biophys Res Commun*. 2021; 561: 65-72.
44. Li Q, Li QQ, Jia JN, Sun QY, Zhou HH, Jin WL, et al. Baicalein Exerts Neuroprotective Effects in FeCl(3)-Induced Posttraumatic Epileptic Seizures via Suppressing Ferroptosis. *Front Pharmacol*. 2019; 10: 638.
45. Thermoziere S, Hou W, Zhang X, Shields D, Fisher R, Bayir H, et al. Anti-Ferroptosis Drug Enhances Total-Body Irradiation Mitigation by Drugs that Block Apoptosis and Necroptosis. *Radiat Res*. 2020; 193: 435-50.
46. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. *Cell Mol Life Sci*. 2016; 73: 3221-47.
47. Saha S, Buttari B, Panieri E, Profumo E, Saso L. An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation. *Molecules*. 2020; 25.
48. Tossetta G, Marzioni D. Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway. *Pharmacol Res*. 2022; 183: 106365.
49. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. *Arch Toxicol*. 2011; 85: 241-72.
50. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. *Arch Biochem Biophys*. 2010; 501: 116-23.
51. Satoh T, McKercher SR, Lipton SA. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. *Free Radic Biol Med*. 2013; 65: 645-57.
52. Kenny EM, Fidan E, Yang Q, Anthony-muthu TS, New LA, Meyer EA, et al. Ferroptosis Contributes to Neuronal Death and Functional Outcome After Traumatic Brain Injury. *Crit Care Med*. 2019; 47: 410-8.
53. Tsang PW, Chau KY, Yang HP. Baicalein exhibits inhibitory effect on the energy-dependent efflux pump activity in non-albicans *Candida* fungi. *J Chemother*. 2015; 27: 61-2.
54. Zhao J, Yang S, Lv C, Liu Y. Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1. *Am J Physiol Cell Physiol*. 2023; 324: C1039-c52.
55. Pan Q, Luo Y, Xia Q, He K. Ferroptosis and Liver Fibrosis. *Int J Med Sci*. 2021; 18: 3361-6.
56. Ortega MA, Fraile-Martinez O, Garcia-Montero C, Funes Moñux RM, Rodriguez-Martín S, Bravo C, et al. The Placentas of Women Who Suffer an Episode of Psychosis during Pregnancy Have Increased Lipid Peroxidation with Evidence of Ferroptosis. *Biomolecules*. 2023; 13.
57. Ortega MA, De Leon-Oliva D, Garcia-Montero C, Fraile-Martinez O, Boaru DL, Del Val Toledo Lobo M, et al. Understanding HAT1: A Comprehensive Review of Noncanonical Roles and Connection with Disease. *Genes (Basel)*. 2023; 14.